Jacob Orme

Jan 23, 2024 | ascopubs.org | Daniel Childs |Jacob Orme

8 which accompanies this editorial, and the recently published EMBARK study, BCR was one of the last remaining prostate cancer disease states without data to support the use of ARPI doublets.9 Moreover, given that the natural history of BCR is often indolent, it is a particularly challenging space to conduct therapeutic trials owing to the lengthy follow-up needed to demonstrate clinical benefit.

Jan 23, 2024 | brnw.ch | Daniel Childs |Jacob Orme

Treating prostate cancer with intensified androgen blockade is widely accepted.

Dec 15, 2023 | urotoday.com | Emmanuel S. Antonarakis |Jacob Orme

Poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA2-mutant cancers are the foremost example of synthetic lethality in prostate cancer. Synthetic lethality is the therapeutic exploitation of a genetic mutation that leads to the death of cancer cells. In BRCA2-altered prostate cancers, the cellular machinery mediating double-strand DNA break repair shifts to rely on PARP enzymes. Thus, PARP inhibitors like olaparib lead to faulty DNA repair and cancer cell death.